Clinical trials: MDS (Myelodysplastic Syndrome)
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00935090
- Testing
- 3'-deoxy-3'-[18F]fluorothymidine
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Leukemia, Hodgkins Disease
Blood Samples to Evaluate Biomarkers of Donor Chimerism
We are interested in patient-specific factors that may affect the balance of recipient cells and donor cells in patients who receive stem cell transplants.
- Conditions
- Leukemia, Hodgkins Disease, Non-hodgkins Lymphoma, Myelodysplastic Syndrome
- Trial name
- NCT00764829
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Lymphoblastic, Acute, Leukemia, Myeloid Acute
Phase I, Dose Escalation Study of Decitabine
Decitabine is a hypomethylating agent that has shown significant anti-leukemic effect in Myelodysplastic Syndrome (MDS) and Acute Myeloblastic Leukemia (AML).
- Conditions
- Leukemia, Lymphoblastic, Acute, Leukemia, Myeloid Acute, Hematopoetic Myelodysplasia
- Trial name
- NCT02264873
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Florida
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies
Cytokine-induced killer ( CIK ) cells have been shown by our lab to be cytolytic against both autologous and allogeneic acute myeloid leukemia ( AML ) cells.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Non Hodgkin's Lymphoma
- Trial name
- alloCIK (NCT00460694)
- Testing
- infusion of allogeneic CIK cells
- Where
- Singapore
- Volunteers
- 24 people
- Sponsor
- Singapore General Hospital
Myelodysplastic Syndromes
A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)
To learn if luspatercept is more effective in helping to reduce the number of blood transfusions needed by patients with LR-MDS.
- Trial name
- NCT06113302
- Testing
- Luspatercept
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Clonal Cytopenia of Undetermined Significance, Myelodysplastic Syndrome
Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)
This is an open-label, phase 2 study for lower risk MDS and high risk CCUS patients who are transfusion independent. There will be two cohorts enrolled at the same time to measure the effect of nicotinamide riboside and…
- Trial name
- ROSS (NCT07579429)
- Testing
- Nicotinamide Riboside, Pterostilbene
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
MDS, Myelodysplastic Syndromes
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Study of the combination of luspatercept in low-risk myelodysplastic syndrom (LR-MDS) without ring sideroblasts (RS) having failed or being ineligible to ESA
- Trial name
- NCT05181735
- Testing
- Luspatercept Injection [Reblozyl], Eprex
- Where
- 41 sites in France, Italy
- Volunteers
- 150 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery
The goal of this project is to conduct a pilot randomized clinical trial (RCT) to evaluate the feasibility of a brief, behavioral intervention to improve recovery following hematopoietic stem cell transplantation (HSCT).
- Conditions
- Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Lymphoid Leukemia
- Trial name
- NCT02955043
- Testing
- Behavioral techniques
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Wisconsin, Madison
Myelodysplastic Syndrome
Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS
Objectives: Primary: To evaluate the response rate of total cytokine-immunotherapy for low-risk myelodysplastic syndromes (MDS). Secondary: To evaluate response duration, survival and side effects of the treatment.
- Trial name
- NCT00520468
- Testing
- Erythropoietin, Cyclosporin A, G-CSF
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes
Follow-up Study of ICUS and CCUS Patients
The proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions has been released by an international consensus group.
- Trial name
- NCT04428489
- Testing
- Observation and necessary supportive care
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Myelodysplastic Syndromes, Leukemia Acute Myeloid
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome
patients with MDS (Myelodysplastic Syndrome) and mutated IDH2 patients will be treated with AG221 (IDH2 inhibitor)
- Trial name
- NCT03744390
- Testing
- AG-221
- Where
- 22 sites in France
- Volunteers
- 68 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
This phase 2 trial studies how well cluster of differentiation 8 (CD8)+ memory T-cells work as a consolidative therapy following a donor non-myeloablative hematopoietic cell transplant in treating patients with leukemia or…
- Conditions
- Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hodgkin Lymphoma
- Trial name
- NCT02424968
- Testing
- Anti-Thymocyte Globulin, Cyclosporine, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Robert Lowsky
Paroxysmal Nocturnal Hemoglobinuria (PNH)
BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy
The purpose of this study was to determine the efficacy and safety of BCX9930 monotherapy for the treatment of PNH compared to continued C5 inhibitor therapy in adult PNH participants with residual anemia despite treatment with a…
- Trial name
- REDEEM-1 (NCT05116774)
- Testing
- Eculizumab, Ravulizumab, BCX9930
- Where
- 7 sites in France, Hungary and 3 more
- Volunteers
- 12 people
- Sponsor
- BioCryst Pharmaceuticals
Amyloidosis, Basal Cell Carcinoma
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and…
- Conditions
- Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma
- Trial name
- NCT07285044
- Testing
- Cancer Therapeutic Procedure, Questionnaire Administration
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
High-risk MDS
Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)
Open-label, randomized multicenter phase III non-inferiority study
- Trial name
- ACROBAT (NCT04184505)
- Testing
- Azacitidine, Standard Chemotherapy, Allogeneic stem cell transplantation
- Where
- 46 sites in Italy
- Volunteers
- 274 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Myelodysplastic Syndromes, Neutropenia
- Trial name
- NCT00003407
- Testing
- amifostine trihydrate, cytarabine, mitoxantrone hydrochloride
- Where
- 4 sites in United States
- Sponsor
- Rush University Medical Center
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Myelodysplastic Syndromes
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes
This study aims at prospectively enrolling a cohort of 400 incident cases of myelodysplastic syndromes (MDS) at diagnosis, to evaluate the impact of recurrent mutations on overall survival and event-free survival, using next…
- Trial name
- MDS04 (NCT02619565)
- Testing
- blood samples
- Where
- France
- Volunteers
- 349 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of quizartinib when given in combination with azacitidine or cytarabine in treating patients with acute myeloid leukemia or myelodysplastic syndrome that have come back…
- Conditions
- FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
- Trial name
- NCT01892371
- Testing
- Azacitidine, Cytarabine, Quizartinib
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes
A Study of ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
This is a Phase 1 study during which patients with low or intermediate-1 risk myelodysplastic syndrome (MDS) will receive investigational study drug ARRY-614. This study has 2 parts.
- Trial name
- NCT00916227
- Testing
- ARRY-614, p38/Tie2 inhibitor; oral
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.